Nature: reveal the selective inhibition of Vista protein on T cells

November 16, 2019 / bioin / - -- Co inhibitory immune receptor may cause T cell dysfunction in cancer patients The blocking antibodies targeting cytotoxic T lymphocyte associated protein 4 (CTLA-4) and programmed cell death 1 (PD-1) partially reverse the effect of CO inhibitory immune receptor, which is becoming the standard treatment for more and more malignant tumors However, many other pathways that make tumors unsuitable for T cells are not fully understood In a new study, researchers from Bristol Myers Squibb reported that Vista (V-domain immunoglobulin suppressor of T cell activation, T cell activation variable domain immunoglobulin inhibitor) protein selectively binds and suppresses T cells The related research results were recently published in the journal Nature, and the title of the paper is "vista is an acid pH selective life for PSGL-1" Picture from nature, 2019, DOI: 10.1038/s41586-019-1674-5 Multiple histidine residues along the edge of Vista extracellular domain mediate the binding of Vista to P-selectin glycoprotein-1 (PSGL-1) After modification, the antibody selectively binding and blocking the interaction in acid environment is enough to reverse Vista mediated immunosuppression in vivo These findings confirm the mechanism by which Vista may be resistant to tumor immune response and the unexpected role of pH in the binding of Vista and PSGL-1 (BIOON Com) reference: Robert J Johnston et al Vista is an acid pH selective life for PSGL-1 Nature, 2019, DOI: 10.1038/s41586-019-1674-5